Amyloid imaging in Alzheimer's disease: Relationships to memory deficits, brain atrophy, and hypometabolism

European Neurological Journal

Volumn 4, Issue 1, 2012, Pages 61-68

  Chételat, Gaël ^a,b   Rowe, Christopher ^a,c   Villemagne, Victor ^a,c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITÉ DE CAEN   (France)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease (AD); Amyloid PET imaging; Glucose hypometabolism; Hippocampus atrophy; Memory; Mild Cognitive Impairment (MCI)

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; ANTERIOR CINGULATE; BRAIN ATROPHY; BRAIN HYPOMETABOLISM; BRAIN METABOLISM; BRAIN REGION; COGNITIVE DEFECT; DEMENTIA; HIPPOCAMPUS; HUMAN; MEMORY DISORDER; NEOCORTEX; NERVE DEGENERATION; NEUROIMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; REVIEW; TEMPORAL CORTEX;

EID: 84871330508     PISSN: 20418000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechan isms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006 Jun;g7(6):1700-1725.
2. Bennett DA. Part I. Epidemiology and public health impact of Alzheimer's disease. Dis Mon. 2000 Oct;46(10):657-665.
3. Schneider J, Murray J, Banerjee S, Mann A. EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I-Factors associated with carer burden. Int J Geriatr Psychiatry. iogg Aug;14(8):651-661.
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002 Oct
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939-944.
6. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurolojia. 2000 Mar;15(3):93-101.
7. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005 JuI;62(7):1160-1163; discussion 1167.
8. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995 Aug;38(2):z54-zs9.
9. Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch. Neurol. 2005 May;62(5):721-728.
10. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. I992 Mar;42(3 Pt. 1):631-639.
11. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999 Sep;155(3):853-862.
12. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999 Dec;46(6):86o-866.
13. McLean CA, Beyreuther K, Masters CL. Amyloid Abeta levels in Alzheimer's disease-A diagnostic tool and the key to understanding the natural history of Abeta? J Alzheimers Dis. 2001 Jun;3(3):305-312.
14. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000 Mar 225283 (I2):1571-1577.
15. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechan isms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006 Jun;97(6):1700-1725.
16. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentia- tion in vivo. Nature. 2002 Apr 4;416(6880):535-539.
17. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol. 2007 Oct;34(7): 809-822.
18. Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol. 2008 Aug;38(l):l-I5.
19. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004
20. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007 May I5;68(20):1718-1725.
21. Maezawa I, Hong H, Liu R, et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem. 2008 Jan;104(2):457-468.
22. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid betapeptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996 Jan;2(1):93-95.
23. Mintun MA, Larossa GN, Sheline YI, et al. [nC]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006 Aug 8;67(3):446-452.
24. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997 Aug;18(4):351-357.
25. Thai DR., Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002 Jun 25;58(12):1791-1800.
26. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007 Mar;64(3):431-434.
27. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008 Jun;131(Pt. 6):163O-1645.
28. Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ. Quanti tative neurohistological features of frontotemporal degeneration. Neuro biol Aging. 2000 Dec;21(6):913-919.
29. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon n-labeled Pittsburgh Compound B. Arch Neurol. 2008 Oct;65(10):1304-1309.
30. Juréus A, Swahn B, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010 Aug;114(3):784-794.
31. Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem. 2010 Feb:53(3):933-941.
32. Shin J, Lee S, Kim SJ, Kim S, Cho S, Kim Y. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage. 2010 Aug 15;52(2):488-496.
33. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J NucI Med. 2010 Jun;51(6):913-920.
34. Shoghi-Jadid K, Small GW, Agdeppa BD, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002 Feb;10(l):24-35.
35. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N EnglJ Med. 2006 Dec 21;355(25):2652-2663.
36. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry. 2009 Jan;66(1):81-87.
37. Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nud Med. 2009 Feb;50(2):191-197.
38. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008 Oct;29(10):l456-I465.
39. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [nC]PIB uptake is increased in mild cognitive impairment. Neurology. 2007 May 8;68(19):1603-1606.
40. Pike KB, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzhei mer's disease. Brain. 2007 Nov;13(Pt. 111):2837-2844.
41. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010 Aug;31(8):1275-1283.
42. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008 Nov;65(12):1509-1517.
43. Villemagne VL, Pike KB, Darby D, et al. Abeta deposits in older non- demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46(6):1688-1697.
44. Forman MS, Mufson EJ, Leurgans S, et al. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology. 2007 Mar 6;68(10):757-763.
45. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001 Oct;17(2):101-118.
46. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc NatI Acad Sci USA. 2009 Apr 21;106(16):6820-6825.
47. Rabinovici GD, Furst AT, Alkalay A, et al. Increased metabolic vulner ability in early-onset Alzheimer's disease is not related to amyloid burden. Brain. 2010 Feb;133(Pt. 25) 512-528.
48. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypoth esis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol. 2008 Jan;63(1):112-118.
49. Roe CM, Mintun MA, Ghoshal N, et al. Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology. 2010 Jul 6;75(1):42-48.
50. Katzman R, Aronson M, Fuld P, et al. Development of dement ing illnesses in an 80-year-old volunteer cohort. Ann Neurol. 1989 Apr;25(4):317-324
51. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006 Jun;20(2):112-117.
52. Hedden T, Van Dijk KRA, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009 Oct 7;29(40):12686-12694.
53. Jack CR, Lowe VJ, Senjem ML, et al. 11C P1B and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008 Mar;131(Pt. 31):665-680.
54. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009 May;65(5):557-568.
55. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009 May;132(Pt. 5):1310-1323.
56. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010 Mar;67(3):353-364
57. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010 Feb;7(1):56-66.
58. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009 Jul 30 :63 (2):178-188.
59. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009 Dec;66(12):1476-1481.
60. Fripp J, Bourgeat P, Acosta O, et al. Appearance modeling of 11C P1B PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage. 2008 Nov
61. Tolboom N, van der Flier WM, Yaqub M, et al. Differential association of [iiC]PIB and [18F]FDDNP binding with cognitive impairment. Neurology. 2009 Dec 15;73(24):2079-2085.
62. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [nC]PIB and [i8F]FDG PET study. Neurology. 2007 Feb 13;68(7):501-508.
63. Furst AJ, Rabinovici GD, Rostomian AH, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging. 2010 Apr 22 [cited 2010 Jul 30] [Epub ahead of print]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20417582
64. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [nC]P1B. Neurology. 2010 Mar 9;74(10):807-815.
65. Chételat G, Villemagne VL, Pike KB, et al. Independent contribution of temporal beta-Amyloid deposition to memory decline in non-demented elderly. Brain, in press.
66. Bourgeat P, Chetelat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010 Jan 12;74(2);121-127.
67. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex, 2009
68. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology. 2009 Apr 28;72(17):15O4-1511.
69. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010 Mar;67(3):317-324.
70. Chetelat G, Villemagne VL, Pike KE, et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain. 2010
71. Fjell AM, Walhovd KB, Reinvang I, et al. Selective increase of cortical thickness in high-performing elderly-structural indices of optimal cognitive aging. Neuroimage. 2006 Feb 1;29(3):984-994.
72. Sole-Padulles C, Bartres-Faz D, Junque C, et al. Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2009 Jul;30(7):1114-1124.
73. Bennett DA, Wilson RS, Schneider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology. 2003 Jun 24;60(12):1909-1915.
74. Ziolko SK, Weissfeld LA, Klunk WE, et al Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006 Oct I5;33(1):94-102.
75. Ng S, Villemagne VL, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J NucI Med. 2007 Apr;48(4):547-552.
76. Li Y, Rjnne JO, Mosconi L, et al. Regional analysis of FDG and PIBPET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J NucI Med Mol Imaging. 2008 Dec;35(12):2160.-2181.
77. Lowe VJ, Kemp BJ, Jack CR, et al. Comparison of 18F-FDG and PiB-PET in cognitive impairment. J NucI Med. 2009 Jun;50(6):878-886.
78. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B [11CPIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Gcriatr Psychiatry Neurol. 2010 Apr 29 [cited 2010 Aug 5] [Epub ahead of print]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20430977
79. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009 Oct I3;73(15):1193-1199.
80. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009 Nov 25;29(47):14770-14778.
81. Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May;6(3):202-211.e7.
82. Ellis KA, Bush Al, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline char acteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychofleriatr. 2009 Aug;21(4):672-687